Cytek Biosciences (CTKB) News Today $5.12 -0.09 (-1.63%) Closing price 03:59 PM EasternExtended Trading$5.20 +0.09 (+1.76%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cytek Biosciences (CTKB) Projected to Post Quarterly Earnings on ThursdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Thursday, February 27, Financial Modeling Prep reports.February 21 at 2:21 AM | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decline in Short InterestCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,170,000 shares, a decrease of 8.6% from the January 15th total of 3,470,000 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 4.0 days.February 18 at 10:19 PM | marketbeat.comCytek BiosciencesFebruary 14, 2025 | forbes.comCytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025February 13, 2025 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Sees Strong Trading Volume - What's Next?February 11, 2025 | marketbeat.comCytek Biosciences to Participate in Upcoming Investor ConferencesFebruary 5, 2025 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock Price Down 4% - Here's WhyCytek Biosciences (NASDAQ:CTKB) Trading Down 4% - Time to Sell?February 4, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading Up 5% - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Shares Up 5% - Should You Buy?February 3, 2025 | marketbeat.comCytek Biosciences price target raised to $5.25 from $4.50 at Goldman SachsFebruary 2, 2025 | markets.businessinsider.comGoldman Sachs cuts Cytek Biosciences stock rating to sellJanuary 31, 2025 | msn.comCytek Biosciences downgraded to Sell from Buy at Goldman SachsJanuary 31, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - What's Next?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - What's Next?January 31, 2025 | marketbeat.comThe Goldman Sachs Group Downgrades Cytek Biosciences (NASDAQ:CTKB) to SellThe Goldman Sachs Group downgraded Cytek Biosciences from a "buy" rating to a "sell" rating and reduced their target price for the company from $7.00 to $4.50 in a research report on Friday.January 31, 2025 | marketbeat.comPiper Sandler Remains a Buy on Cytek Biosciences (CTKB)January 31, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Down 5.5% - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Trading Down 5.5% - Time to Sell?January 29, 2025 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the companyJanuary 27, 2025 | finance.yahoo.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What HappenedJanuary 17, 2025 | marketbeat.comCytek Biosciences sees FY24 revenue $200M-$201M, consensus $204.71MJanuary 16, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Time to Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?January 15, 2025 | marketbeat.comCytek Biosciences shares take a hit after Q4 sales miss estimatesJanuary 15, 2025 | in.investing.comCytek Biosciences Shares Fall On Low Preliminary 4Q RevenueJanuary 15, 2025 | marketwatch.comCytek Biosciences Announces Preliminary Full Year 2024 Revenue ResultsJanuary 15, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Hold Rating for Cytek Biosciences (CTKB)January 14, 2025 | markets.businessinsider.comBarclays PLC Has $1.12 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)Barclays PLC raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 333.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,359 shares of the company's stock after buyingJanuary 14, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading 5.9% Higher - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Shares Up 5.9% - Should You Buy?January 13, 2025 | marketbeat.comUpgrading Cytek Biosciences Stock On An Upcoming CatalystJanuary 9, 2025 | seekingalpha.comCytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest UpdateCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 3,690,000 shares, a drop of 6.6% from the November 30th total of 3,950,000 shares. Approximately 3.2% of the company's stock are sold short. Based on an average trading volume of 661,700 shares, the short-interest ratio is currently 5.6 days.December 31, 2024 | marketbeat.comCytek Biosciences board approves $50M stock repurchase programDecember 31, 2024 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) to Buyback $50.00 million in Stock Cytek Biosciences (NASDAQ:CTKB - Get Free Report) announced that its board has authorized a stock buyback program on Monday, December 30th, RTT News reports. The company plans to buyback $50.00 million in shares. This buyback authorization permits the company to reacquire up to 5.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its stock is undervalued.December 30, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Price Up 5.9% - Should You Buy?Cytek Biosciences (NASDAQ:CTKB) Trading Up 5.9% - Here's What HappenedDecember 30, 2024 | marketbeat.comCytek Biosciences Announces $50 Million Stock Repurchase Program for 2025December 30, 2024 | globenewswire.comGeode Capital Management LLC Buys 89,210 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Geode Capital Management LLC boosted its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 3.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,668,004 shares of the company's stock after acquiring aDecember 30, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Acquired by Barclays PLCBarclays PLC boosted its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 333.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,359 shares of the company's stock after buyinDecember 30, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by State Street CorpState Street Corp grew its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 4.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,167,501 shares of the company's stock after purchasing an additional 194December 23, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Price Up 4.8% - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Trading 4.8% Higher - What's Next?December 18, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Stock Holdings Lessened by Wellington Management Group LLPWellington Management Group LLP lessened its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 6.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,007,139 shares of the company's stoDecember 16, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Down 5.4% - Here's WhyCytek Biosciences (NASDAQ:CTKB) Trading Down 5.4% - Time to Sell?December 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 113,127 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Charles Schwab Investment Management Inc. boosted its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 12.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,030,962 shares of the company's stock aDecember 13, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Buys New Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)Jacobs Levy Equity Management Inc. bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 182,713 shares ofDecember 9, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)November 26, 2024 | markets.businessinsider.comBrown Capital Management LLC Has $52.59 Million Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Brown Capital Management LLC cut its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 16.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,493,474 shares of the company's stock after selling 1,893,910 shaNovember 21, 2024 | marketbeat.comCytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | globenewswire.comCytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramNovember 19, 2024 | globenewswire.comCautious Hold on Cytek Biosciences Amid Recovery and Growth OpportunitiesNovember 19, 2024 | markets.businessinsider.comCytek Biosciences, Inc. (NASDAQ:CTKB) Sees Large Decline in Short InterestCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 4,200,000 shares, a decline of 6.0% from the October 15th total of 4,470,000 shares. Approximately 3.6% of the company's shares are sold short. Based on an average daily volume of 673,900 shares, the short-interest ratio is presently 6.2 days.November 18, 2024 | marketbeat.comCytek Biosciences price target raised to $8.50 from $8 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comPiper Sandler Issues Positive Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock PricePiper Sandler boosted their target price on shares of Cytek Biosciences from $8.00 to $8.50 and gave the stock an "overweight" rating in a report on Monday.November 11, 2024 | marketbeat.comCytek Biosciences introduces ESP Detection Option for Cytek AuroraNovember 7, 2024 | markets.businessinsider.comCytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterNovember 7, 2024 | globenewswire.com Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Media Mentions By Week CTKB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTKB News Sentiment▼0.630.60▲Average Medical News Sentiment CTKB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTKB Articles This Week▼32▲CTKB Articles Average Week Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 10x Genomics News Transcat News Senseonics News Standard BioTools News Allient News EyePoint Pharmaceuticals News Aehr Test Systems News Quanterix News Quantum-Si News Nautilus Biotechnology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTKB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
